Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression Auspex Pharmaceuticals, a developer of next-generation
medicines with improved safety and performance through the targeted deuteration of clinically validated
drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI).
Source: www.medicalnewstoday.comFDA Advisory Committee Provides Clear Path Forward For Development Of Amyloid Imaging Agents For Alzheimer's Disease Avid Radiopharmaceuticals announced that the U.S. Food and Drug Administration (FDA) Peripheral and CNS Advisory Committee provided strong support for development of amyloid imaging agents to test for the presence or absence of Alzheimer's disease pathology in people with symptoms of cognitive impairment.
Source: www.medicalnewstoday.comRacialization Of Drugs Mobilizes Prior Conceptions Of Identity If we want to fully understand the allure of pharmaceuticals, we need to look beyond both medical efficacy and profit motives. A new study in the Journal of Law,
Medicine & Ethics shows that when we use claims about
drugs in arguments about racial identity, the meaning of both the pharmaceuticals and of race remain unsettled. Anne Pollock, Ph.D.
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
